ArticleInternational journal of hematology2020
A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Coagulation potential of concomitant factor VIII administration in people with hemophilia A receiving emicizumab prophylaxis (CAGUYAMA study): a multicenter, open-label, nonrandomized clinical trial.Research and practice in thrombosis and haemostasis · 2026Trial
- Trial
- Laboratory Challenges in the Era of Novel Haemophilia Therapies.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Review
- Factor VIII administration during emicizumab prophylaxis: how much is enough?Research and practice in thrombosis and haemostasis · 2026Article
- Procoagulant Effect of FIX Concentrates and Bypass Agents in Combination with Emicizumab and Impact of FVIII Inhibitors.Biomedicines · 2026Article
- Emicizumab enhances the ex vivo coagulant potential in plasma samples from patients with von Willebrand disease.International journal of hematology · 2026Article
- Emicizumab, the factor VIII mimetic bispecific monoclonal antibody: effects on thrombin generation and thromboelastometry.Research and practice in thrombosis and haemostasis · 2025Article
- Factor X and combined factor VIIa/factor X augment coagulation potential in a plasma model of antithrombin-reduced hemophilia.Research and practice in thrombosis and haemostasis · 2025Article
- Thrombin Generation Assay to Support Hematologists in the Era of New Hemophilia Therapies.International journal of laboratory hematology · 2025Review
- The in vitro cross-reactivity and blood coagulation potential of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A.International journal of hematology · 2025Article
- Factor X consumption attenuates the coagulation effect of emicizumab: a case of severe hemophilia A treated with emicizumab and factor VIII-bypassing agents.International journal of hematology · 2025Article
- Extending health equity to people with moderate and mild hemophilia A: revisiting the HAVEN 6 trial.Research and practice in thrombosis and haemostasis · 2025Article
- Article
- Ex vivo evaluation of the effect of plasma-derived factor VIII/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis.Clinical and experimental medicine · 2024Article
- Thrombin generation to evaluate the complex hemostatic balance of hemophilia A plasma containing direct oral anticoagulant and supplemented by factor VIII.Research and practice in thrombosis and haemostasis · 2024Article
- Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma.International journal of hematology · 2024Article
- NXT007-mediated hemostatic potential is suppressed by activated protein C-catalyzed inactivation of activated factor V.Research and practice in thrombosis and haemostasis · 2024Article
- Article
- Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine.Journal of thrombosis and haemostasis : JTH · 2021Review
- Monitoring of Coagulation Potential of Efanesoctocog Alfa in Haemophilia A: Insights From Conventional and Global Hemostasis Assays.Haemophilia : the official journal of the World Federation of HemophiliaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Emicizumab shortens activated partial thromboplastin time (aPTT) greater than Factor (F)VIII. Clot waveform analysis triggered by ellagic acid and tissue factor trigger (Elg/TF) provided a useful means of assessing emicizumab activity. Thrombin generation assays (TGA) using this trigger reagent might also overcome the difficulties associated with aPTT by emicizumab. To compare TGA triggered by Elg/TF and other reagents (FXIa, TF) for evaluating emicizumab activity. Emicizumab, FVIII, or FVIII-bypassing agents (BPAs) were incubated with FVIII-deficient plasmas prior to TGA initiated by Elg/TF (0.2 μM/0.5 pM), FXIa (5.21 pM), or TF (PPP-Reagent LOW
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.